Mkts

Aligos Therapeutics, Inc.

NASDAQ: ALGS
$1.22-0.03 (-2.40%)
As of Nov 20, 4:00 PM ET

Key statistics

Day range
1.181.34
52-week range
1.2213.69
Today
Open1.26
Previous close1.22
Volume40.2K
Valuation
Market cap8.60M
P/E ratio—
EPS (TTM)-7.31
Income & risk
Dividend / yield—
Beta2.86
Avg volume80.1K
Discussion

ALGS News

Stories mentioning ALGS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue2,830169.00741.00965.00311.00606.001,2501,061
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development23,35217,03823,93713,97614,50216,03016,77421,099
Sales General & Admin
Total Operating Expenses29,75921,98329,10219,53219,55421,19221,40027,475
Operating Income (Loss)(26,929)(21,814)(28,361)(18,567)(19,243)(20,563)(20,131)(26,414)
Interest Income
Interest Expense
Other Expense
Pretax Income(22,723)(19,851)(31,481)(15,678)43,131(82,123)(19,168)5,250
Tax Provision317.0030.0056.00185.0043.0027.0091.00189.00
Net Income (Loss)(23,040)(19,881)(31,537)(15,863)43,088(82,150)(19,259)5,061
Earnings Per Share (Basic)(2.21)(2.01)(3.04)(1.53)5.12(13.11)(3.07)0.81
Earnings Per Share (Diluted)(2.21)(2.01)(3.04)(1.53)(2.11)(13.11)(3.07)0.81
Weighted Average Shares Outstanding (Basic)10,4039,88510,37010,3518,4086,2656,2726,258
Weighted Average Shares Outstanding (Diluted)10,4039,88510,37010,3518,7106,2656,2726,266

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About ALGS

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a stock listed on the Nasdaq Stock Market under the ticker symbol ALGS. It last traded at $1.22 (Nov 20, 2026, 4:00 PM ET), down 2.4% on the day. That gives Aligos Therapeutics a market capitalisation of $8.6M.

Over the past 52 weeks ALGS has traded between $1.22 and $13.69.

Revenue for the quarter ended Mar 31, 2026 was $2.8M; a net loss of $23.0M. Revenue was up 810% from $311.0K in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$2.8M-$23.0M-814.1%
Dec 31, 2025$169.0K-$19.9M-11763.9%
Sep 30, 2025$741.0K-$31.5M-4256.0%
Jun 30, 2025$965.0K-$15.9M-1643.8%

From Aligos Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…